GlaxoSmithKline: regulatory applications for new HIV therapy
(CercleFinance.com) - Shares of GlaxoSmithKline are slightly up today after the British drugmaker submitted regulatory applications for a first HIV maintenance regimen comprising only two medicines.
GSK and its subsidiary ViiV Healthcare yesterday announced regulatory submissions to the European Medicines Agency and US FDA for a single-tablet, two-drug regimen of dolutegravir and rilpivirine for the maintenance treatment of HIV-1 infection.
Traditionally, physicians use a regimen of three or more drugs to maintain HIV viral suppression.
After the announcement, Bryan Garnier reiterated its "buy" recommendation on the stock, with a 1,750 pence fair value, citing "good news" for the company.
The brokerage firm thinks this novel two-drug regimen could be approved as early as Q4 2017 and also believes that this shows that ViiV Healthcare remains a "significant growth driver for the company."
GSK shares are currently up 0.7% at 1,715.5 pence.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
GSK and its subsidiary ViiV Healthcare yesterday announced regulatory submissions to the European Medicines Agency and US FDA for a single-tablet, two-drug regimen of dolutegravir and rilpivirine for the maintenance treatment of HIV-1 infection.
Traditionally, physicians use a regimen of three or more drugs to maintain HIV viral suppression.
After the announcement, Bryan Garnier reiterated its "buy" recommendation on the stock, with a 1,750 pence fair value, citing "good news" for the company.
The brokerage firm thinks this novel two-drug regimen could be approved as early as Q4 2017 and also believes that this shows that ViiV Healthcare remains a "significant growth driver for the company."
GSK shares are currently up 0.7% at 1,715.5 pence.
Copyright (c) 2017 CercleFinance.com. All rights reserved.